EISAI CO

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Public

Established: 1941-12-06

Employees: 11K

Market Cap: $12B

Website: http://www.eisai.co.jp

Clinical Trials

Study of E3810 for Healthy Japanese Male (Under Fasting Condition)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: rabeprazole

First Posted Date: 2010-03-12

Last Posted Date: 2013-05-13

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT01085695

Pharmacokinetics Study of Donepezil HCl in Subjects Receiving Haemodialysis.

Phase 4

Completed

Conditions: End-Stage Renal Disease

Interventions: Drug: donepezil HCl

First Posted Date: 2010-02-05

Last Posted Date: 2013-05-14

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 6

Registration Number: NCT01063556

A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)

Phase 1

Completed

Conditions: Insomnia

Interventions: Drug: Eszopiclone 3 mg
Drug: Eszopiclone 1 mg

First Posted Date: 2010-01-26

Last Posted Date: 2013-02-12

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 42

Registration Number: NCT01055834

A Study of MORAb-003 in Patients With Solid Tumor

Phase 1

Completed

Conditions: Neoplasms
Solid Tumor

Interventions: Drug: MORAb-003

First Posted Date: 2010-01-14

Last Posted Date: 2020-06-11

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT01049061

A Study of MORAb-009 in Patients With Solid Tumor

Phase 1

Completed

Conditions: Cancer
Mesothelin-positive

Interventions: Drug: MORAb-009

First Posted Date: 2009-11-25

Last Posted Date: 2016-01-21

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 17

Registration Number: NCT01018784

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: T-614
Drug: Placebo

First Posted Date: 2009-08-26

Last Posted Date: 2021-12-17

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 253

Registration Number: NCT00965757

Study of E7389 for Advanced or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Eribulin Mesylate

First Posted Date: 2009-08-25

Last Posted Date: 2013-08-15

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 81

Registration Number: NCT00965523

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

Phase 1

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Lenvatinib

First Posted Date: 2009-07-24

Last Posted Date: 2019-02-01

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 66

Registration Number: NCT00946153

A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: E7050

First Posted Date: 2009-06-16

Last Posted Date: 2017-12-26

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT00921869

A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)

Phase 2

Completed

Conditions: Refractory Partial Seizures

Interventions: Drug: perampanel

First Posted Date: 2009-05-18

Last Posted Date: 2018-08-29

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 21

Registration Number: NCT00903786

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy